1-Bromo-4-methoxybutane (cas: 4457-67-4) belongs to organobromine compounds. Bromo compounds are employed in a variety of metal-catalyzed coupling reactions. They are also ideal candidates for the synthesis of Grignard reagents that have wide-applicability in organic synthesis. When the molecular ion is detected, the bromine and chlorine isotope patterns are very distinct, but caution is to be exercised for certain mixed chlorinated/brominated compounds, which can look similar to homohalogen patterns.Recommanded Product: 1-Bromo-4-methoxybutane
Bicyclic Ligand-Biased Agonists of S1P1: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles was written by Gilmore, John L.;Xiao, Hai-Yun;Dhar, T. G. Murali;Yang, Michael;Xiao, Zili;Yang, Xiaoxia;Taylor, Tracy L.;McIntyre, Kim W.;Warrack, Bethanne M.;Shi, Hong;Levesque, Paul C.;Marino, Anthony M.;Cornelius, Georgia;Mathur, Arvind;Shen, Ding Ren;Pang, Jian;Cvijic, Mary Ellen;Lehman-McKeeman, Lois D.;Sun, Huadong;Xie, Jenny;Salter-Cid, Luisa;Carter, Percy H.;Dyckman, Alaric J.. And the article was included in Journal of Medicinal Chemistry in 2021.Recommanded Product: 1-Bromo-4-methoxybutane This article mentions the following:
Sphingosine-1-phosphate (S1P) binds to a family of sphingosine-1-phosphate G-protein-coupled receptors (S1P1-5). The interaction of S1P with these S1P receptors has a fundamental role in many physiol. processes in the vascular and immune systems. Agonist-induced functional antagonism of S1P1 has been shown to result in lymphopenia. As a result, agonists of this type hold promise as therapeutics for autoimmune disorders. The previously disclosed differentiated S1P1 modulator BMS-986104 (1) exhibited improved preclin. cardiovascular and pulmonary safety profiles as compared to earlier full agonists of S1P1; however, it demonstrated a long pharmacokinetic half-life (T1/2 18 days) in the clinic and limited formation of the desired active phosphate metabolite. Optimization of this series through incorporation of olefins, ethers, thioethers, and glycols into the alkyl side chain afforded an opportunity to reduce the projected human T1/2 and improve the formation of the active phosphate metabolite while maintaining efficacy as well as the improved safety profile. These efforts led to the discovery of 12 and 24, each of which are highly potent, biased agonists of S1P1. These compounds not only exhibited shorter in vivo T1/2 in multiple species but are also projected to have significantly shorter T1/2 values in humans when compared to our first clin. candidate. In models of arthritis, treatment with 12 and 24 demonstrated robust efficacy. In the experiment, the researchers used many compounds, for example, 1-Bromo-4-methoxybutane (cas: 4457-67-4Recommanded Product: 1-Bromo-4-methoxybutane).
1-Bromo-4-methoxybutane (cas: 4457-67-4) belongs to organobromine compounds. Bromo compounds are employed in a variety of metal-catalyzed coupling reactions. They are also ideal candidates for the synthesis of Grignard reagents that have wide-applicability in organic synthesis. When the molecular ion is detected, the bromine and chlorine isotope patterns are very distinct, but caution is to be exercised for certain mixed chlorinated/brominated compounds, which can look similar to homohalogen patterns.Recommanded Product: 1-Bromo-4-methoxybutane
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary